ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Japan’s Astellas Pharma and Ambit Biosciences will codevelop AC220, Ambit’s treatment for acute myeloid leukemia, a fatal form of blood cancer. Astellas will make an initial cash payment of $40 million to San Diego-based Ambit and pay as much as $350 million to the firm if the product gains approval. AC220 is a kinase inhibitor that recently entered Phase II clinical trials. Separately, Japan’s Eisai will pay $255 million to acquire New Jersey-based AkaRx, which has developed AKR-501, an agonist for thrombopoietin receptors, which stimulate platelet production.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X